Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) investigational Cell Pouch Bio-Hybrid Organ has shown encouraging clinical trial results, and its pipeline is intriguing, but the biotech needs cash to advance its clinical programs next year, reported Dr. Andre Uddin, Research Capital Corp. analyst, in a June 16 research note.
The clinical-stage cell therapy biotech company is developing a cell replacement therapy platform aimed at functionally curing several diseases including type 1 diabetes (T1D), hypothyroidism and hemophilia A.
"Cell Pouch is well-positioned in the T1D clinical development landscape," Uddin wrote. "We continue to believe that the company will need to secure additional funding in the near term," Uddin wrote.
275% Implied Return
Research Capital maintained its CA$0.60 per share target price, reported Uddin. He noted that positive data from the upcoming Cohort C of the ongoing Phase 1/2 clinical trial in T1D could be "a meaningful value inflection point."
The biotech's share price at the time of Uddin's report was CA$0.16 per share, the analyst noted. From there, the return to target is 275%.
Sernova is a Speculative Buy. Its market cap as of June 16 is CA$52.56 million (CA$52.56M). Its 52-week range is CA$0.15–0.39 per share.
Capital Raised in Q2/25
Uddin reported that at the end of Q2/26, the biotech had US$2M in cash and US$4.2M in debt.
During Q2, in mid-April, Sernova raised US$4M from Navigate Private Yield Fund LP III, managed by Fraser Mackenzie Private Credit Inc. This loan is secured against the assets of Sernova, its U.S. subsidiary and Dr. Steven Sangha, a board member. The loan matures on April 16, 2026, and accrues fixed interest of US$400K for the first six months then at 14.25% per annum thereafter.
Sernova also raised US$1M through a convertible debenture financing with Sangha. The biotech issued him 9 million common share purchase warrants, exercisable at US$0.20 per share for 36 months and subject to a four-month trading hold from the issuance date.
"The recent debt financing rounds extend Sernova's cash runway through approximately Q4/25," Uddin wrote.
To that end, Sernova currently is looking into funding opportunities with GoldTrack Ventures and the Kingdom of Saudi Arabia, potential sources of capital.
'Earnings Remain Less Important'
During Q2/25, as Research Capital expected, Sernova did not generate any revenue, like in 2024.
The biotech reported a net loss of US$3.8M, an improvement over Q2/24's greater net loss of US$9.9M. In comparison, Research Capital's net loss estimate for Sernova was higher at US$5.3M.
"Earnings remain less important at this stage as Sernova continues to operate as a clinical-stage cell therapy biotech company," wrote Uddin.
Positive Interim Data
Sernova announced interim data from its Phase 1/2 T1D clinical trial, which were positive. Reported results were for Cohort A patients, implanted with the 8-channel Cell Pouch, and for the ongoing Cohort B patients, implanted with the 10-channel Cell Pouch.
Eight out of 12 patients achieved insulin independence, and seven out of 12 patients maintained functional islet cell activity demonstrated by C-peptide levels greater than 0.3 nanograms per milliliter. BETA and BETA-2 scores and Cell Pouch histology supported functionality of the transplanted islet cells. As for glycemic control, nine out of 12 patients showed HbA1c levels below 7%, the American Diabetes Association's recommended threshold.
Of the other three patients, one improved to 7.8% from a baseline of 10.3%, and the other two dropped below 7% from baseline, where their levels stayed.
"We believe the trial is on track to meet its primary and secondary endpoints," Uddin commented.
The primary endpoint is the safety and tolerability of the Cell Pouch following implantation, and islet transplantation.
Secondary outcome measures are: survival of endocrine tissue in the Cell Pouch, proportion of patients with fewer hypoglycemic events at three points in the study; and proportion of participants with a reduction in HbA1c greater than 1mg%, at three points in the study after final Cell Pouch transplant.
Changes in Leadership
Uddin reported the company's changes to management. Chair Ross Haghighat resigned, so Sernova has appointed its chief executive officer Jonathan Rigby as interim chair until it finds a replacement. Also, Chief Business Officer Dr. Modestus Obochi left the company.
Further, in late May, Sernova created a clinical advisory board, all in the diabetes or endocrinology field. Dr. Robert Gbbay is the board chair, and members are Dr. Mark Atkinson, Dr. Melena Bellin, Dr. Andrew Posselt and Dr. Holger Russ.
Near-Term Catalysts
Investors should watch for enrollment of Cohort C patients for this same study, who will be implanted with the 10-channel Cell Pouch and receive optimized immunosuppression. This process is to begin before 2025 ends. Subsequently, Cohort C will be dosed, and this component of the study will be completed in 2026.
Also next year, Sernova will initiate its trial using Evotec's induced pluripotent stem cells.
| Want to be the first to know about interesting Medical Devices investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
- Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Research Capital Corp., Sernova Biotherapeutics Inc., June 16, 2025
Analyst Certification I, Andre Uddin, Ph.D., certify the views expressed in this report were formed by my review of relevant company data and industry investigation, and accurately reflect my opinion about the investment merits of the securities mentioned in the report. I also certify that my compensation is not related to specific recommendations or views expressed in this report. Each analyst of Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst’s personal views and (ii) no part of the research analyst’s compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report. Relevant Disclosures Applicable to Companies Under Coverage Information about Research Capital Corporation's Rating System, the distribution of our research to clients and the percentage of recommendations which are in each of our rating catergories is available on our website at www.researchcapital.ca General Disclosures Research Capital Corporation publishes research and investment recommendations for the use of its clients. The opinions, estimates and projections contained in all Research Reports published by Research Capital Corporation ("RCC") are those of RCC as of the date of publication and are subject to change without notice. RCC makes every effort to ensure that the contents have been compiled or derived from sources believed to be reliable and that contain information and opinions that are accurate and complete; RCC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions which may be contained therein and accepts no liability whatsoever for any loss arising from any use of or reliance on its Research Reports or its contents. Information may be available to RCC that is not contained therein. Contents of this report cannot be reproduced in whole or in part without the express permission of Research Capital Corporation. Research Reports disseminated by RCC are not a solicitation to buy or sell. All securities not available in all jurisdictions. Distribution Policy Through www.researchcapital.com, our institutional and corporate clients can access our research as soon as it becomes available, 24-7. New reports are continually uploaded to the site as they become available throughout the day. Clients may also receive our research via Reuters, Bloomberg, FactSet, and Capital IQ. All of our research is made widely available at the same time to all Research Capital client groups entitled to our research. In addition, research reports are sent directly to our clients based on their delivery preference (mail, fax, e-mail). Fair Dissemination of Research Reports and Ratings To the extent reasonably practicable, Research Reports will be disseminated contemporaneously to all of Research Capital Corporation ("RCC") customers who are entitled to receive the firm's research. Until such time, Research Analysts will not discuss the contents of their reports with Sales and Trading or Investment Banking employees. RCC equity research is posted to our proprietary website to ensure eligible clients receive coverage initiations and changes in rating, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax or regular mail. Please contact your Investment Advisor or Portfolio Manager for more information regarding RCC research. Percentage Distribution of Research Ratings As required by the Canadian Investment Regulatory Organization, Research Capital provides a summary of the percentage of its recommendations that fall into each category of our ratings. Our distribution of ratings is available on our website at www.researchcapital.com Information regarding our categories of recommendations, quarterly summaries of the percentage of our recommendations which fall into each category and our policies regarding the release of our research reports is available at www.researchcapital.com or may be requested by contacting the analyst. Potential Conflicts of Interest All Research Capital Corporation ("RCC") Analysts are compensated based in part on the overall revenues of RCC, a portion of which are generated by investment banking activities. RCC may have had, or seek to have, an investment banking relationship with companies mentioned in this report. RCC and/or its officers, directors and employees may from time to time acquire, hold or sell securities mentioned in our Research Reports as principal or agent. RCC makes every effort possible to avoid conflicts of interest, however readers should assume that a conflict might exist, and therefore not rely solely on this report when evaluating whether or not to buy or sell the securities of subject companies. Research Capital Corporation, its directors, officers and other employees may, from time to time, have positions in the securities mentioned herein. RC USA INC. US Institutional Clients – Research Capital USA Inc., a wholly owned subsidiary of Research Capital Corporation, accepts responsibility for the contents of this report. This report has been created by analysts who are employed by Research Capital Corporation, a Canadian Investment Dealer. US firms or institutions receiving this report should effect transactions in securities discussed in the report through Research Capital USA Inc., a Broker – Dealer registered with the Financial Industry Regulatory Authority (FINRA). Member – Canadian Investor Protection Fund / membre – fonds canadien de protection des épargnants
